P2RX5 Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q93086 |
---|---|
Clone Names | 100507049 |
Gene ID | 5026 |
---|---|
Other Names | P2X purinoceptor 5, P2X5, ATP receptor, Purinergic receptor, P2RX5, P2X5 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP14059b was selected from the C-term region of P2RX5. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | P2RX5 |
---|---|
Synonyms | P2X5 |
Function | Receptor for ATP that acts as a ligand-gated ion channel. |
Cellular Location | Membrane; Multi-pass membrane protein. |
Tissue Location | Expressed at high levels in brain and immune system |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
The product of this gene belongs to the family ofpurinoceptors for ATP. This receptor functions as a ligand-gatedion channel. Several characteristic motifs of ATP-gated channelsare present in its primary structure, but, unlike other members ofthe purinoceptors family, this receptor has only a singletransmembrane domain. Three transcript variants encoding distinctisoforms have been identified for this gene.
References
Kotnis, S., et al. Mol. Pharmacol. 77(6):953-960(2010)Overes, I.M., et al. Cancer Immunol. Immunother. 58(3):429-439(2009)Dubyak, G.R. Mol. Pharmacol. 72(6):1402-1405(2007)Lamesch, P., et al. Genomics 89(3):307-315(2007)Duckwitz, W., et al. J. Biol. Chem. 281(51):39561-39572(2006)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.